Julie Kim

Representative Director, President and CEO, Takeda

About

Julie Kim is Representative Director, President and Chief Executive Officer of Takeda Pharmaceutical Company Limited, the Japan-headquartered drug maker. The board appointed her to the role on June 24, 2026, after the shareholder meeting, and she succeeded Christophe Weber. She joined Takeda in 2019 through its acquisition of Shire and previously led the company's U.S. business and its plasma-derived therapies business.

Takeda's annual report gives her birth year as 1970. She joined Shire in June 2016 as head of international value demonstration and access, and in May 2018 became head of its global hematology franchise. At Takeda she started in January 2019 as president of the Plasma-Derived Therapies Business Unit and has been a member of the Takeda Executive Team since then. From April 2022 she was president of the U.S. Business Unit. Whoo also has pages for leaders of other drug makers, such as Novartis CEO Vas Narasimhan and Novo Nordisk CEO Mike Doustdar.

Takeda's October 2026 semi-annual report lists her as Representative Director, President and CEO.

Whoo compiled this page from public sources: Takeda annual report (Form 20-F, 2026), Takeda news release, June 2026, BioSpace, January 2025, Takeda Form 6-K, October 2026. It is not affiliated with or endorsed by Julie Kim. Are you Julie Kim? Claim this page, or write to [email protected] to correct or remove it. Last updated: 2026-11-18.

Want a page like this? Create yours from your résumé.

Experience

Representative Director, President and Chief Executive Officer — Takeda


June 2026 – Present

  • Succeeded Christophe Weber
  • President, U.S. Business Unit — Takeda


    April 2022

  • Also U.S. Country Head

President, Plasma-Derived Therapies Business Unit — Takeda


January 2019

Head of Global Hematology Franchise — Shire


May 2018

Head of International Value Demonstration and Access — Shire


June 2016

Education

Education


Not published in sources

Projects